Celecoxib Efficacy And Safety Versus Diclofenac In Acute Pain Due To Cervical Sprain Related To A Traffic Accident

Pain Clinical Trial

Official title:

A Phase IV Open Label Randomized Multicenter Comparative Study Of Celecoxib Efficacy And Safety Versus Standard Doses Of Oral Diclofenac In Acute Pain Due To Cervical Sprain Related To Motor Vehicle Accident

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00894790
• Other study ID #: A3191352
• Status: Terminated
• Phase: Phase 4
• Start date: November 2009
• Est. completion date: January 2010

Study information

• Verified date: January 2021
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Study Will Evaluate Celecoxib Efficacy And Safety Versus Standard Doses Of Diclofenac In Acute Pain Due To Cervical Injury (Due To A Sprain) Related To A Motor Vehicle Accident

Description:

On 21Oct2010 study was prematurely terminated due to poor enrollment with subsequent low number of participants. No safety or efficacy issues were involved in the decision to terminate prematurely.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients That Had Suffered A Car Accident And Due To It Suffered A Cervical Sprain

Exclusion Criteria:

• Recent Cervical Sprains Or Other Cervical Conditions

Related Conditions & MeSH terms

• Acute Pain
• Pain
• Sprains and Strains

Intervention

Drug:
• Celecoxib
celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
• oral Diclofenac
diclofenac 75 mg tablet BID (twice a day)

Locations

Country	Name	City	State
Mexico	Pfizer Investigational Site	Mexico	D.f.
Mexico	Pfizer Investigational Site	Mexico	D.f.

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to Day 7 of Participant's Assessment of Cervical Pain Due to Cervical Sprain	Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).	Baseline, Day 7
Secondary	Change From Baseline on VAS-pain at Day 3 and Day 14	Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).	Baseline, Days 3, 14
Secondary	Percentage of Participants With at Least a 20 mm Improvement on VAS-pain (Responder Rates)	Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain) with at least a 20 mm improvement.	Baseline, Days 7, 14
Secondary	Change From Baseline in Patient Global Assessment of Cervical Injury	Participant rated responses to question: Considering all the ways your cervical injury affects you, how are you doing today? Response options ranged from 1 (Very good - No symptoms and no limitation of normal activities) to 5 (Very Poor - Very severe symptoms which are intolerable and inability to carry out all normal activities).	Baseline, Days 7, 14
Secondary	Change From Baseline on Physician's Global Assessment of Cervical Injury	Physician rated responses evaluating the overall condition of participant's cervical injury at that time. Response option ranged from 1 (Very mild - Very mild signs and symptoms of cervical injury) to 5 (Very Severe - Very severe signs and symptoms of cervical injury).	Baseline, Days 7, 14
Secondary	Change From Baseline in Modified Brief Pain Inventory-Short From (m-BPI-sf): Pain Interference Score	m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely intereres) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours.	Baseline, Days 7, 14
Secondary	Modified Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores	m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level).	Baseline, Days 7, 14
Secondary	Change From Baseline in Categorical Responses to Participant's Gastrointestinal (GI) Symptom Questionnaire	Two part questionnaire; First part assessed symptoms: feeling of gas/air in stomach or feeling bloated, nausea, vomiting, excessive burping or belching and worsening of heartburn or acid reflux. Participant rated Yes/No experienced, for how many days per week (1 through 7) for each symptom and how bothered they were (not at all, somewhat or very). Second part assessed the presence of general abdominal pain (steady, dull, sharp/shooting, always present or comes and goes), the number of days they experienced it (1 through 7) and how bothered they were by it (not at all, somewhat, very).	Baseline, Days 7, 14
Secondary	Change From Baseline in Participant's Responses to Neck Disability Index (NDI)	NDI: participant-administered 10-item questionnaire to assess how neck pain affects 10 activities of daily living (pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation) with six potential responses, each describing a greater degree of disability (0 = no disability to 5 = total disability). Total score calculated by adding individual item scores for evaluation scheme: 0-5 = No disability; 6-15 = Mild disability; 16-25 = Moderate disability; 26-35 = Severe disability; Above 35 = Complete disability.	Baseline, Days 7, 14

External Links

•   To obtain contact information for a study center near you, click here.